Andrew Jensen

Andrew Jensen is an associate in Goodwin’s Antitrust and Competition practice. He advises clients on antitrust and competition issues, including merger reviews, compliance, government antitrust investigations, antitrust litigation, and other regulatory issues. He has significant experience in premerger counseling, including compliance with Hart-Scott-Rodino premerger requirements, and has also successfully guided clients through investigations before the DOJ and FTC. Andrew has experience counseling clients across a wide range of industries, including healthcare, pharmaceuticals, financial services, consumer products, retail, manufacturing, among others.

Andrew is committed to pro bono service, including successfully representing clients in asylum merits hearings, in collaboration with Catholic Charities Immigration Legal Services, Community Legal Services in East Palo Alto (CLSEPA), and Lawyers for Good Government.

Andrew’s representative experience includes advising:

• iRobot in its proposed acquisition by Amazon
• Inversago Pharma in its acquisition by Novo Nordisk, worth up to $1.08 billion
• PPD in its $17.4 billion acquisition by Thermo Fisher Scientific*
• Change Healthcare’s $13.8 billion acquisition by Optum*
• Hellman & Friedman in its acquisition of The NPD Group*
• BMC Stock Holdings in its $5.5 billion merger with Builders FirstSource*
• Waystar in its acquisition of eSolutions*

*Denotes experience prior to joining Goodwin.

Andrew’s recent publications include:

• Co-author, “United States: DOJ and FTC to Shift Focus to AI as Stringent Merger Enforcement Chills Tech Deals,” Global Competition Review’s Digital Markets Guide, October 2, 2024
• Co-author, “Antitrust & Competition Healthcare Quarterly Update Q2 2024,” Goodwin Insight, September 18, 2024
• Co-author, “Indiana Enacts Broad Notification Requirements for Healthcare Transactions with a Clear Focus on Private Equity,” Goodwin Insight, May 20, 2024
• Co-author, “Antitrust & Competition Healthcare Year in Review 2023,” Goodwin Insight, March 11, 2024
• Co-author, “FTC and DOJ Launch New Cross-Government Inquiry on the Role of Private Equity in Healthcare,” Goodwin Insight, March 7, 2024
• Co-author, “US Antitrust Agencies Release Final Revised Merger Guidelines,” Goodwin Insight, December 19, 2023
• Co-author, “Antitrust & Competition Healthcare Quarterly Update Q3 2023,” Goodwin Insight, November 2, 2023
• Co-author, “US Antitrust Regulators Continue to Crack Down on Interlocking Directorates, and the FTC Expands Scope of Clayton Act to Noncorporate Entities,” Goodwin Insight, August 25, 2023
• Co-author, “Antitrust & Competition Healthcare Quarterly Update Q2 2023,” Goodwin Insight, August 11, 2023